BioCentury
ARTICLE | Clinical News

Inclisiran: Ph II ORION-2 started

February 1, 2017 9:45 PM UTC

The Medicines Co. began the open-label, Dutch Phase II ORION-2 trial to evaluate 300 mg subcutaneous inclisiran in about 10 patients. Patients whose mean serum PCSK9 levels are not suppressed by >70%...